Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510913
Status:
COMPLETED
Last Update Posted:
2007-08-02
First Post:
2007-07-31
Brief Title:
A Study to Compare the Conversion to Prograf Tacrolimus to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
Prograf Tacrolimus as Secondary Intervention vs Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CRAF
Brief Summary:
A study to compare the conversion to Prograf tacrolimus to the continuation of cyclosporine in patients at risk for chronic renal allograft failure
Detailed Description:
A two arm study 1 Active 1 Active control to compare the incidence progression and severity of chronic renal allograft failure in at-risk patients who are converted from cyclosporine-based to tacrolimus-based immunosuppression to patients who remain on cyclosporine-based therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None